AstraZeneca stock dives 9% after heart drug trial misses target
Shares of AstraZeneca fell as much as 9% after a late stage clinical trial for an experimental heart disease failed to meet its target. The medicine, Wainua, did not reach its main goal of reducing deaths and recurrent heart-related emergencies over 140 weeks compared to a placebo, the British drugmaker said in a press release…
